Lupin has informed that it enclosed a Press release regarding launch of Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials, on receipt of U.S. FDA approval to the Company’s alliance partner Caplin Steriles for its ANDA.
The above information is a part of company’s filings submitted to BSE.